Evidence exists that the risk for a wide range of chronic diseases increases with age. For many of these diseases effective pharmacological interventions are lacking. Hence, any intervention that can slow aging can also reduce the potential of contracting such illnesses. Although several compounds are currently under investigation for their life span extending effects, the complexity of the aging phenotype makes this search difficult. In this project we combine two emerging strategies for drug discovery, namely in silico pharmacology and the use of invertebrate whole-animal models.
Aim 1 will provide a collection of candidate compounds by performing a large-scale bioinformatics screen of over 1,300 pharmacological agents. To do this we will utilize a novel gene list comparison algorithm we have developed to identify significant associations between expression changes induced by drug treatment and expression changes observed in interventions that extend healthspan.
Aim 2 will test the effect of drugs identified in Aim 1 in Drosophila melanogaster. Flies will be fed each compound over the course of their adult life, and their life span as well as their response to stressors will be monitored and compared to that of flies on control food. The proposed work will develop an important new bioinformatics strategy to screen for longevity drugs and has the potential to identify several novel compounds that extend life span.
Aim 3 will utilize the same data collected in Aim 1 but will use a complementary approach in which shared regulatory elements will be identified in the promoters of the genes in the common signatures between drugs and healthspan interventions.
Because aging is the leading risk factor for many chronic illnesses, interventions that can slow aging have the potential to significantly reduce the impact of such diseases and extend healthspan in humans. The comprehensive research design of this proposal has the potential to identify novel pharmacological compounds that can slow aging in model organisms, and ultimately lead to the development of drugs to ameliorate some of the deleterious consequences of aging and age-related disorders in humans.
|Grizotte-Lake, Mayara; Vaishnava, Shipra (2018) Autophagy: Suicide Prevention Hotline for the Gut Epithelium. Cell Host Microbe 23:147-148|
|Atkinson, Elizabeth Grace; Audesse, Amanda Jane; Palacios, Julia Adela et al. (2018) No Evidence for Recent Selection at FOXP2 among Diverse Human Populations. Cell 174:1424-1435.e15|
|Zabat, Michelle A; Sano, William H; Wurster, Jenna I et al. (2018) Microbial Community Analysis of Sauerkraut Fermentation Reveals a Stable and Rapidly Established Community. Foods 7:|
|Lee, Kayla M; Morris-Love, Jenna; Cabral, Damien J et al. (2018) Coinfection With Influenza A Virus and Klebsiella oxytoca: An Underrecognized Impact on Host Resistance and Tolerance to Pulmonary Infections. Front Immunol 9:2377|
|Crane, Meredith J; Lee, Kayla M; FitzGerald, Ethan S et al. (2018) Surviving Deadly Lung Infections: Innate Host Tolerance Mechanisms in the Pulmonary System. Front Immunol 9:1421|
|Crane, Meredith J; Xu, Yun; Henry Jr, William L et al. (2018) Pulmonary influenza A virus infection leads to suppression of the innate immune response to dermal injury. PLoS Pathog 14:e1007212|
|Zabat, Michelle A; Sano, William H; Cabral, Damien J et al. (2018) The impact of vegan production on the kimchi microbiome. Food Microbiol 74:171-178|
|Cabral, Damien J; Wurster, Jenna I; Belenky, Peter (2018) Antibiotic Persistence as a Metabolic Adaptation: Stress, Metabolism, the Host, and New Directions. Pharmaceuticals (Basel) 11:|
|Sugden, Lauren Alpert; Atkinson, Elizabeth G; Fischer, Annie P et al. (2018) Localization of adaptive variants in human genomes using averaged one-dependence estimation. Nat Commun 9:703|
|Cabral, Damien J; Penumutchu, Swathi; Norris, Colby et al. (2018) Microbial competition between Escherichia coli and Candida albicans reveals a soluble fungicidal factor. Microb Cell 5:249-255|
Showing the most recent 10 out of 17 publications